Biolevate provides an AI platform for life sciences teams to manage regulated operations through evidence-driven, auditable workflows.
Biolevate has raised $34.4M in total funding. The most recent round was Series A. The last funding was announced in September 2026.
Biolevate's investors include Bpifrance, EQT Ventures, Orange Ventures, STATION F, Mehdi Ghissassi.
Biolevate is headquartered in Paris, France.
Biolevate provides an AI platform for life sciences teams to manage regulated operations through evidence-driven, auditable workflows.
Biolevate is at the Series A stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Biolevate — Funding & Investors." VCBacked, September 21, 2026, https://www.vcbacked.co/company/biolevate. Accessed October 26, 2026.
VCBacked. (2026). Biolevate — Funding & Investors. Retrieved October 26, 2026, from https://www.vcbacked.co/company/biolevate
{{cite web |title=Biolevate — Funding & Investors |url=https://www.vcbacked.co/company/biolevate |website=VCBacked |access-date=October 26, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated